Calls Purchased on Nektar Therapeutics (NKTR)

Shares of Nektar Therapeutics NKTR are higher on the session, currently trading at $12.98. The stock has been drifting lower for the past three months, but the stock has found support at the 200-day moving average. It is now nearing the 50-day moving average from the downside. Options traders are picking up calls on the name today. The July $12.50 call was purchased on the offer 2,000 times, open interest on the strike is 2,047 contracts. Call volume is running at 3x the daily average with 98% of all calls traded being purchases on the offer. Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology.